Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Company Overview

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..

Key Stats

• Today's Range: $16.70 to $16.70
• 50-Day Range: $16.40 to $16.70
• 52-Week Range: $4.24 to $16.72
• Volume: N/A
• Average Volume: 157,287 shs
• Market Capitalization: $380.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ORTX Stock Analysis - Frequently Asked Questions

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $1.49. The firm had revenue of $1.24 million for the quarter, compared to analyst estimates of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%.

When did Orchard Therapeutics' stock split?

Shares of Orchard Therapeutics reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Orchard Therapeutics IPO?

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchard Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/15/2023
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ORTX
• CUSIP: N/A
• CIK: 1748907
• Web: www.orchard-tx.com
• Phone: 442038088286
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-150,660,000.00
• Net Margins: -333.90%
• Pretax Margin: -334.54%
• Return on Equity: -74.94%
• Return on Assets: -33.51%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.12
• Quick Ratio: 2.98

Sales & Book Value

• Annual Sales: $22.66 million
• Price / Sales: 16.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.74 per share
• Price / Book: 2.16

Miscellaneous

• Outstanding Shares: 22,760,000
• Free Float: 22,099,000
• Market Cap: $380.09 million
• Optionable: Optionable
• Beta: 0.55